Company / Total Assets
Taysha Gene Therapies, Inc. Total Assets History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$343.3M
FY2025
5-year range
$126.3M / $343.3M
FY2021-FY2025
Trend
+114.1%
vs FY2024
Sector context
#172 of 214
Health Care
What the data says
Taysha Gene Therapies, Inc.'s total assets of $343M is lower than 80% of companies in the Health Care sector (FY2025). Total Assets has fluctuated over the past 6 years, ranging from $126M in FY2022 to $343M in FY2025.
Based on SEC 10-K filings.
$343M in FY2025 with a 5-year CAGR of +5.8%.
Improved from $173M to $343M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +39.6%
- 5-Year CAGR
- +5.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 214This company $343.3M Sector average $7.5B
▼
-95.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.8%, indicating consistent growth.
- In FY2025, total assets increased 114.1% year-over-year.
- Ranks #172 out of 214 companies in the Health Care sector.
- Lowest total assets in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $343.3M | +114.1% |
| FY2024 | $160.4M | -7.2% |
| FY2023 | $172.7M | +36.8% |
| FY2022 | $126.3M | -41.0% |
| FY2021 | $214.0M | -17.4% |
| FY2020 | $258.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026